Proteome profiles of vaginal fluids from women affected by bacterial vaginosis and healthy controls: Outcomes of rifaximin treatment

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2648-2659

  Cruciani, Federica ^a   Wasinger, Valerie ^b   Turroni, Silvia ^a   Calanni, Fiorella ^c   Donders, Gilbert ^d   Brigidi, Patrizia ^a   Vitali, Beatrice ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Alfa Wassermann SpA   (Italy)

^d Departments of Obstetrics and Gynaecology   (Belgium)

Author keywords

Antibiotics; Innate immune response; MS MS analysis; Vaginal fluid proteome

Indexed keywords

PLACEBO; PROTEIN; PROTEOME; RIFAXIMIN;

ADULT; ANALYZER; ARTICLE; BACTERIAL VAGINOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MULTICENTER STUDY; ORBITRAP MASS ANALYZER; RANDOMIZED CONTROLLED TRIAL; TABLET; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; VAGINA DISCHARGE; VAGINITIS;

ANTIBIOTICS; INNATE IMMUNE RESPONSE; MS/MS ANALYSIS; VAGINAL FLUID PROTEOME;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BODY FLUIDS; FEMALE; HUMANS; MIDDLE AGED; PROTEOME; RIFAMYCINS; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; VAGINA; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 84886243224     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt244     Document Type: Article

References (39)

1. Dasari S, Pereira L, Reddy AP et al. Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res 2007; 6: 1258-68.
2. Tang LJ, De Seta F, Odreman F et al. Proteomic analysis of human cervical-vaginal fluids. J Proteome Res 2007; 6: 2874-83.
3. Zegels G, Van Raemdonck GA, TjalmaWA et al. Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome Sci 2010; 8: 63.
4. Bigelow J.L., Dunson DB, Stanford JB et al. Mucus observations in the fertile window: a better predictor of conception than timing of intercourse. Hum Reprod 2004; 19: 889-92.
5. Donders GG, Van Calsteren C, Bellen G et al. Association between abnormal vaginal flora and cervical length as risk factors for preterm birth. Ultrasound Obstet Gynecol 2010; doi:10.1002/uog.7568.
6. Hillier SL, Holmes KK, Marrazzo JM. Bacterial vaginosis. In: Holmes KK, Sparling PF, Ma°rdh PA et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill, 2008; 737-68.
7. Vitali B, Pugliese C, Biagi E et al. Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol 2007; 73: 5731-41.
8. Atashili J, Poole C, Ndumbe PM et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22: 1493-501.
9. Schwebke JR. New concepts in the etiology of bacterial vaginosis. Curr Infect Dis Rep 2009; 11: 143-7.
10. Bradshaw CS, Morton AN, Hocking J et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193: 1478-86.
11. Donders GG, Guaschino S, Peters K et al. A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis. Int J Gynaecol Obstet 2013; 120: 131-6.
12. Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther 2011; 33: 812-27.
13. Bajaj JS, Heuman DM, Sanyal AJ et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8: e60042.
14. Maccaferri S, Vitali B, Klinder A et al. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010; 65: 2556-65.
15. Cruciani F, Brigidi P, Calanni F et al. Efficacy of rifaximin vaginal tablets in the treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota. Antimicrob Agents Chemother 2012; 56: 4062-70.
16. Kolialexi A, Mavrou A, Spyrou G et al. Mass spectrometry-based proteomicsin reproductive medicine. MassSpectromRev 2008;27:624-34
17. Fang X, Zhang WW. Affinity separation and enrichment methods in proteomic analysis. J Proteomics 2008; 71: 284-303.
18. Balu RB, Savitz DA, Ananth CV et al. Bacterial vaginosis, vaginal fluid neutrophil defensins, and preterm birth. Obstet Gynecol 2003; 101: 862-8.
19. Fan SR, Liu XP, Liao QP. Humandefensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis. Int J Gynaecol Obstet 2008; 103: 50-4.
20. Valore EV, Wiley DJ, Ganz T. Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun 2006; 74: 5693-702.
21. Shah SJ, Yu KH, Sangar V et al. Identification and quantification of preterm birth biomarkers in human cervicovaginal fluid by liquid chromatography/tandem mass spectrometry. J Proteome Res 2009; 8: 2407-17.
22. Scigelova M, Makarov A. Orbitrap mass analyzer-overview and applications in proteomics. Proteomics 2006; 6 Suppl 2: S16-21.
23. Ly L, Wasinger VC. Peptide enrichment and protein fractionation using selective electrophoresis. Proteomics 2008; 8: 4197-208.
24. Wasinger V, Ly L, Fitzgerald A et al. Prefractionation, enrichment, desalting and depleting of low volume and low abundance proteins and peptides using the MF10. Methods Mol Biol 2008; 424: 257-75.
25. Donders GG, Van Calsteren K, Bellen G et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG 2009; 116: 1315-24.
26. Gatlin CL, Kleemann GR, Hays LG et al. Protein identification at the low femtomole level from silver-stained gels using a new fritless electrospray interface for liquid chromatography-microspray and nanospray mass spectrometry. Anal Biochem 1998; 263: 93-101.
27. Karp NA, McCormick PS, Russell MR et al. Experimental and statistical considerations to avoid false conclusions in proteomics studies using differential in-gel electrophoresis. Mol Cell Proteomics 2007; 6: 1354-64.
28. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-5.
29. Fredricks DN, Fiedler TL, Thomas KK et al. Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis asassessedbyquantitativePCR. J Clin Microbiol2009;47:721-26.
30. Drell T, Lillsaar T, Tummeleht L et al. Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. PLoS One 2013; 8: e54379.
31. Ling Z, Kong J, Liu F et al. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics 2010; 11: 488.
32. Ravel J, Gajer P, Abdo Z et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4680-7.
33. Srinivasan S, Hoffman NG, Morgan MT et al. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationshipsofmicrobiotatoclinical criteria.PLoSOne2012;7:e37818.
34. Cauci S, Scrimin F, Driussi S et al. Specific immune response against Gardnerella vaginalis hemolysin in patients with bacterial vaginosis. Am J Obstet Gynecol 1996; 175: 1601-5.
35. Eade CR, Diaz C, Wood MP et al. Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLoS One 2012; 7: e50106.
36. Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 2007; 21: 355-73.
37. Donders GG, Vereecken A, Bosmans E et al. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG 2002; 109: 34-43.
38. Beigi RH, YudinMH,Cosentino L et al. Cytokines, pregnancy,andbacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. J Infect Dis 2007; 196: 1355-60.
39. Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene 2005; 348: 1-11.